报价延迟最少15分钟:2026/04/23 23:54 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.69 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.74/-0.54
|
|
企业价值
410.77M
|
| 资产负债 |
|
每股账面净值
5.54
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
216.11M
|
|
每股收益
4.03
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada. |
